Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Breast Neoplasms 19Neoplasms 11Polycystic Ovary Syndrome 9Neoplasm Metastasis 4Multiple Myeloma 4Melanoma 4Vomiting 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Leiomyoma 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Ovarian Neoplasms 2Obesity 2Nausea 2Myofibroma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, B-Cell 2Leukemia 2Insulin Resistance 2Inflammation 2Infertility, Female 2

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × Tablets × Clear all
NCT04722575 2025-03-13

NEO-TIM

Fondazione Melanoma Onlus

Phase 2 Active not recruiting
95 enrolled
Dermatologic

Melanoma

NCT05370807 2023-10-24

RegoMel

Universitair Ziekenhuis Brussel

Phase 2 Unknown
48 enrolled
Dermatologic

Melanoma

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00083252 2007-06-08

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡